报价延迟最少15分钟:2024/12/25 00:29 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.5 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.53/-2.07
|
|
企业价值
41.94M
|
| 资产负债 |
|
每股账面净值
1.48
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
10.96M
|
|
每股收益
1.75
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2024/12/25 00:29 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel. |